Y. Berd

Evaluation of the safety, pharmacokinetics and treatment effects of an ανβ3 integrin inhibitor on bone turnover and disease activity in men with hormone‐refractory prostate cancer and bone metastases

M. Campone, M. Rosenthal, A. Lombardi, 2010, Asia-Pacific journal of clinical oncology.

The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial.

A. Jensen, G. Ramírez, A. Lombardi, 2010, Clinical breast cancer.

A Randomized, Double‐Blind, Placebo‐Controlled, Sixteen‐Week Study of Subcutaneous Golimumab in Patients With Active Nonradiographic Axial Spondyloarthritis

M. Dougados, D. M. van der Heijde, D. Heijde, 2015, Arthritis & rheumatology.

MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study.

D. Papanicolaou, J. Chandler, A. Adunsky, 2011, Archives of gerontology and geriatrics.

Effect of cathepsin k inhibition on suppression of bone resorption in women with breast cancer and established bone metastases in a 4-week, double-blind, randomized controlled trial

A. Jensen, G. Ramírez, A. Lombardi, 2008 .